Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Supernus Pharmaceuticals Inc
F:S49
Supernus Pharmaceuticals Inc
F:S49
Price:
39.2
EUR
5.38%
Market Closed
Market Cap:
€2.2B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
S
|
Supernus Pharmaceuticals Inc
F:S49
|
US |
|
Henry Boot PLC
F:0KH
|
UK |
|
P
|
Permian Resources Corp
XMUN:YZ8
|
US |
|
CIR SpA - Compagnie Industriali Riunite
MIL:CIR
|
IT |
|
P
|
Pultegroup Inc
XMUN:PU7
|
US |
|
A
|
Avient Corp
SWB:PY9
|
US |
|
K
|
KEFI Gold and Copper Plc
OTC:KFFLF
|
CY |
Wall St Price Targets
S49 Price Forecast
Based on 8 analysts
Based on 8 analysts
+82% Upside
from
€39.2
today
Supernus Pharmaceuticals Inc (S49)’s 12-month stock price forecast through September 2027 has a consensus target of €71.33, implying 82% upside. The forecast is based on price targets from 8 Wall Street analysts.
S49 Analyst Rating
No ratings yet
No ratings yet
Supernus Pharmaceuticals Inc Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is S49's stock price target?
Price Target
71.33
EUR
71.33
EUR
According to Wall Street analysts, the average 1-year price target for S49 is 71.33 EUR with a low forecast of 59.77 EUR and a high forecast of 75.69 EUR.
What is the Revenue forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
8%
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 61%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
7%
7%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 59%. The projected CAGR for the next 8 years is 7%.
What is the Operating Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
61%
61%
The compound annual growth rate for Operating Income over the next 8 years is 61%.